RxDoctor Payments Data

Elisabeth Okroi

Nurse Practitioner · Oklahoma City, OKNPI 1356865414

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,234 of the $4,727 with a category attached, or 68.4%. 18 manufacturers reported payments, led by Axonics, Inc. at 32.0% of the total. Among nurse practitioner clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,727in general payments, 2019–2025

Across 97 payments — averaging $48.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Hollister Incorporated$1K
  • Coloplast$508
  • Medtronic$394
  • Boston Scientific$224
  • Convatec Inc.$199
  • plus $865 from 12 others

What the payments were for

  • Speaking & faculty fees$75016%
  • Travel & lodging$74316%
  • Food & beverage$3,23468%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,727 in reported general payments places this provider in the 90th percentile of 824 nurse practitioner providers in Oklahoma.

See all nurse practitioner providers in Oklahoma

Medicare billing

Part B allowed, 2024
$48,265
Medicare patients
312
Services billed
718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron74$52,602
MyrbetriqMirabegron42$28,818
Tamsulosin Hcl159$2,263
Solifenacin Succinate35$2,262
Estradiol33$2,071
Trospium Chloride25$1,347
Finasteride59$1,098
Potassium Citrate ErPotassium Citrate11$1,065
Oxybutynin Chloride ErOxybutynin Chloride31$493
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst27$417
Ciprofloxacin Hcl36$241
NitrofurantoinNitrofurantoin Macrocrystal13$190
Cephalexin27$148
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim25$144
Allopurinol12$27

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$75$52,60274 claims
Astellas Pharma US IncMyrbetriq$51$28,81842 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 824 nurse practitioner providers in Oklahoma.

Other nurse practitioner in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →